Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX) from its SEC filings: 2025 revenue $726.4 million (+4% vs the year before), net margin 1%, free cash flow $136.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $726.4 million |
| Revenue growth | +4% |
| Net income | $7.0 million |
| Net margin | 1.0% |
| Free cash flow | $136.7 million |
| Diluted EPS | $0.16 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $205.9 million |
| Long-term debt | $363.1 million |
| Share count, 1 year | -11% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.